1. Volume 69, Issue 4, Pages 968-970 (October 2018)
Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission 
Astrid M. Newsum, Richard Molenkamp, Jan T. van der Meer, Sjoerd P. Rebers, Maria Prins, Marc van der Valk, Janke Schinkel 
Journal of Hepatology 
Volume 69, Issue 4, Pages (October 2018)
DOI: /j.jhep
Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
HCV RNA dynamics during and following five HCV infections in a HIV-infected MSM. Blue boxes indicate HCV genotype. Black boxes indicate period of HCV treatment. Arrows indicate when S282T was present. t0 to t2 indicate key time points which are described in the text (t0 = treatment initiation of sofosbuvir/ledipasvir; t1 = 12 weeks after treatment initiation; t2 = 26 weeks after treatment initiation). HCV, hepatitis C virus; PR, (pegylated)-interferon-alpha/ribavirin; SOF/DCV, sofosbuvir/daclatasvir; SOF/LDV, sofosbuvir/ledipasvir; SOF/GZR/EBR/R, sofosbuvir/grazoprevir/elbasvir/ribavirin.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2018 European Association for the Study of the Liver Terms and Conditions